Mesoblast to Present at 35th Annual J.P. Morgan Healthcare Conference
January 11 2017 - 6:00AM
Mesoblast (Nasdaq:MESO) (ASX:MSB) will host a live audio webcast at
the 35th Annual J.P. Morgan Healthcare Conference. Mesoblast’s
management will present on Thursday, January 12, 2017 at 7:30
a.m. PST/2.30 a.m. Friday, January 13, 2017 (AEDT).
What: Mesoblast Presentation at
the 35th Annual J. P. Morgan Healthcare Conference
When: Thursday, January 12, 2017
at 7.30 a.m. PST/2.30 a.m. Friday, January 13, 2017 (AEDT).
Where:
http://jpmorgan.metameetings.com/confbook/healthcare17/directlink?p=22962
How: Log on to the live webcast at
the address above and register for the event approximately 10
minutes before the scheduled start time. The archived webcast will
be available in the Events and Presentations section of the
Company's website (www.mesoblast.com).
About MesoblastMesoblast Limited (ASX:MSB;
Nasdaq:MESO) is a global leader in developing innovative cell-based
medicines. The Company has leveraged its proprietary technology
platform, which is based on specialized cells known as mesenchymal
lineage adult stem cells, to establish a broad portfolio of
late-stage product candidates. Mesoblast’s allogeneic,
‘off-the-shelf’ cell product candidates target advanced stages of
diseases with high, unmet medical needs including cardiovascular
diseases, immune-mediated and inflammatory disorders, orthopedic
disorders, and oncologic/hematologic conditions.
Forward-Looking StatementsThis press release
includes forward-looking statements that relate to future events or
our future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance or achievements to differ
materially from any future results, levels of activity, performance
or achievements expressed or implied by these forward-looking
statements. We make such forward-looking statements pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995 and other federal securities laws. Forward-looking
statements should not be read as a guarantee of future performance
or results, and actual results may differ from the results
anticipated in these forward-looking statements, and the
differences may be material and adverse. You should read this press
release together with our risk factors, in our most recently filed
reports with the SEC or on our website. Uncertainties and risks
that may cause Mesoblast's actual results, performance or
achievements to be materially different from those which may be
expressed or implied by such statements, and accordingly, you
should not place undue reliance on these forward-looking
statements. We do not undertake any obligations to publicly update
or revise any forward-looking statements, whether as a result of
new information, future developments or otherwise.
For further information, please contact:
Julie Meldrum
Corporate Communications
T: +61 3 9639 6036
E: julie.meldrum@mesoblast.com
Schond Greenway
Investor Relations
T: +1 212 880 2060
E: schond.greenway@mesoblast.com
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Sep 2023 to Sep 2024